WO2012077774A1 - Dispositif pour la prophylaxie et le traitement du lupus érythémateux systémique - Google Patents

Dispositif pour la prophylaxie et le traitement du lupus érythémateux systémique Download PDF

Info

Publication number
WO2012077774A1
WO2012077774A1 PCT/JP2011/078506 JP2011078506W WO2012077774A1 WO 2012077774 A1 WO2012077774 A1 WO 2012077774A1 JP 2011078506 W JP2011078506 W JP 2011078506W WO 2012077774 A1 WO2012077774 A1 WO 2012077774A1
Authority
WO
WIPO (PCT)
Prior art keywords
hsp90
serum
blood
concentration
sle
Prior art date
Application number
PCT/JP2011/078506
Other languages
English (en)
Japanese (ja)
Inventor
保明 田村
昇志 佐藤
俊彦 鳥越
慶太 齋藤
Original Assignee
北海道公立大学法人 札幌医科大学
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 北海道公立大学法人 札幌医科大学 filed Critical 北海道公立大学法人 札幌医科大学
Priority to JP2012547917A priority Critical patent/JP5916135B2/ja
Publication of WO2012077774A1 publication Critical patent/WO2012077774A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3679—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by absorption

Definitions

  • the present invention relates to an apparatus for preventing and treating systemic lupus erythematosus, a method for use as a biomarker for systemic lupus erythematosus, and a method for determining systemic lupus erythematosus.
  • SLE Systemic lupus erythematosus
  • SLE Systemic lupus erythematosus
  • Clinical symptoms vary, including fever, anemia, thrombocytopenia, butterfly erythema, erythematous rash, polyarthralgia, serositis, renal symptoms, neurological symptoms, and cardiac symptoms.
  • SLE Although the details of the cause of SLE are not yet clear, it is thought to develop due to involvement of environmental factors such as ultraviolet rays, viral infection, trauma, surgery, pregnancy, childbirth, and drug treatment in addition to genetic factors.
  • high serum interferon ⁇ is considered to be one of the causes of disease progression.
  • Diagnosis of SLE is [1] cheek butterfly erythema, [2] characteristic rash occurring elsewhere, [3] hypersensitivity to sunlight, [4] ulcers in the mouth, [5] arthritis, [6] Water accumulates around lungs, heart, and other organs (serositis), [7] Kidney dysfunction, [8] Decrease in white blood cell count, decrease in red blood cell count due to hemolytic anemia, decrease in platelet count , [9] Brain or nerve dysfunction, [10] Antinuclear antibody reaction positive in blood test, [11] Anti-double-stranded DNA antibody positive in blood test, corresponding to 4 or more items This is done by confirming that However, since some of these diagnostic items include severe symptoms, new diagnostic items have been sought in order to enable a more complete early diagnosis.
  • non-steroidal anti-inflammatory drugs such as aspirin are used when symptoms are mild, and corticosteroid drugs such as prednisolone are mainly used when symptoms are severe.
  • corticosteroids have anti-inflammatory and immunosuppressive effects, SLE improves the inflammation of organ lesions caused by SLE and suppresses the production of autoantibodies and the action of autoreactive lymphocytes. It is considered to exert therapeutic effects on
  • corticosteroids not only reduce the human defense function, but may also worsen high blood pressure, heart failure, diabetes, peptic ulcer, renal failure, osteoporosis, etc. Careful attention is required.
  • Patent Document 1 discloses that an adenine-derived compound having the ability to inhibit PDE4 family enzymes and substituted at positions 2 and 9 and optionally N (6) of adenine can be used for the treatment of SLE. Is disclosed. However, such compounds are premised on use in combination with corticosteroids. Under such circumstances, there has been a demand for a new treatment method for SLE with fewer side-effect problems.
  • heat shock protein is an intracellular protein whose expression increases by heat shock, and is known to increase in response to stresses such as radiation and malnutrition other than heat.
  • the heat shock protein functions as a molecular chaperone that forms complexes with various proteins in the cell, stabilizes the protein, and functions normally, and in particular, the client protein of heat shock protein 90 (Hsp90)
  • Hsp90 heat shock protein 90
  • signaling molecules that play an important role in cell proliferation and differentiation, such as protein kinases and steroid hormone receptors. It is also known that heat shock protein forms a complex with a peptide and is released from tumor cells and infected cells to the outside when exposed to stress, thereby contributing to an immune response.
  • Non-Patent Document 1 describes that Hsp90 activates interferon ⁇ and interferon ⁇ , and that the antiviral effect of interferon ⁇ and interferon ⁇ is suppressed by geldanamycin, an inhibitor of Hsp90.
  • Patent Document 2 describes that Hsp90 activates tumor necrosis factor ⁇ (Tumor Necrosis Factor ⁇ : TNF ⁇ ) and interleukin 6 (IL-6), and claim 21 inhibits Hsp90. Methods have been described for reducing TNF ⁇ and IL-6 by administering a substance to a patient such as systemic lupus erythematosus (SLE).
  • SLE systemic lupus erythematosus
  • Non-Patent Document 2 by the present inventors describes that Hsp90 forms a complex with its own DNA (Hsp90-self DNA complex), thereby suppressing the degradation of self-DNA, and that self-DNA is It is suggested that human plasmacytoid dendritic cells promote interferon alpha production by efficiently incorporating them into plasmacytoid dendritic cells and localizing their own DNA to the early endosomes of plasmacytoid dendritic cells. ing. Further, Non-Patent Document 3 describes that Hsp90 expression is increased in peripheral blood mononuclear cells in SLE patients. However, since Hsp90 is not a secreted protein, its concentration in the serum of SLE patients was not expected to be significantly increased and was not known.
  • An object of the present invention is to provide a systemic lupus erythematosus prevention / treatment device, a method for use as a biomarker for systemic lupus erythematosus, and a method for determining systemic lupus erythematosus.
  • the present inventors have previously studied the relationship between SLE and Hsp90, and that Hsp90 inhibitors inhibit interferon ⁇ production from plasmacytoid dendritic cells and preventive / therapeutic effects of SLE. (Japanese Patent Application No. 2010-219422). As a result of intensive studies under the circumstances described in the background art described above, the present inventors have found that [a] the Hsp90 concentration is extremely high in the serum of SLE patients at the stage of disease progression, [b ] In the serum of SLE patients in remission after treatment, the concentration of Hsp90 is reduced to the same level as in healthy individuals, and [c] The serum from which Hsp90 has been removed from the serum of SLE patients is human plasmacytoid.
  • the interferon ⁇ concentration in the culture supernatant when added to the dendritic cell and cultured is the same as the interferon ⁇ in the culture supernatant when the serum of the SLE patient is added to the human plasmacytoid dendritic cell and cultured.
  • the inventors have found that the concentration is remarkably reduced as compared with the concentration, and have completed the present invention.
  • the present invention is characterized in that (1) a systemic lupus erythematosus prevention / treatment device comprising a removal means for Hsp90, and (2) the removal means for Hsp90 contains a removal substance for Hsp90.
  • the present invention also relates to (4) a method of using Hsp90 in blood, serum or plasma as a biomarker for systemic lupus erythematosus.
  • the present invention comprises (5) a method for determining systemic lupus erythematosus, comprising the following steps (A) and (B): (A) a step of measuring in vitro the concentration of Hsp90 in the blood, serum or plasma of a subject; (B) a step of comparing and evaluating the Hsp90 concentration measured in the step (A) with the Hsp90 concentration in blood, serum or plasma of a normal control; (6) The determination method according to (5), further comprising the following step (C) or (D): (C) A step of evaluating the subject as systemic lupus erythematosus when the Hsp90 concentration measured in the step (A) is higher than the Hsp90 concentration in blood, serum or plasma of a normal control; (D) The degree of the Hsp90 concentration measured in the step (A) is higher than the Hsp90 concentration in blood, serum or plasma of a normal control, and the severity of the pathological condition of systemic lupus ery
  • systemic lupus erythematosus can be prevented and / or treated with few side effects. Moreover, according to the present invention, a new biomarker for systemic lupus erythematosus can be provided. Furthermore, according to the present invention, systemic lupus erythematosus can be determined quickly and easily.
  • “Healthy donor” represents the result of a healthy person, and ⁇ in the figure represents the concentration of each person.
  • Before treatment represents the result in the case of symptom exacerbation of SLE patients.
  • After treatment represents the result in the post-treatment remission period of the SLE patient, and the ⁇ in the figure indicates the concentration of each patient. It is a figure which shows the interferon (alpha) density
  • Control represents the result when no serum was added
  • “stimulated with SLE patient serum” represents the result when the serum of the SLE patient was added
  • concentration in serum of a SLE onset model mouse “MRL / lpr mice 21w” represents the results at 21 weeks of age before the onset, and the ⁇ mark in the figure indicates the concentration of each mouse.
  • “MRL / lpr mice 28w” represents the results of 28 weeks of age at the onset of the onset, and the ⁇ marks in the diagram indicate the concentration of each mouse.
  • “MRL / lpr mice 37w” represents the results of 37 weeks of age in the late stage of the onset, and the ⁇ in the figure indicates the concentration of each mouse.
  • systemic Lupus Erythematosus Prevention / Treatment Device The “systemic lupus erythematosus prevention / treatment device” of the present invention (hereinafter also simply referred to as “the prevention / treatment device of the present invention”) is a means for removing Hsp90 (hereinafter simply referred to as “prevention / treatment device of the present invention”). As long as it includes “Hsp90 removing means”), there is no particular limitation.
  • the prophylactic / therapeutic device of the present invention allows Hsp90 in the blood, serum or plasma of a subject to After removal, the blood, serum, or plasma is returned to the subject to reduce the Hsp90 concentration in the subject's blood, serum, or plasma, thereby interferon of the subject's plasmacytoid dendritic cells It is considered that a prophylactic and / or therapeutic effect on SLE is exhibited through suppression of ⁇ production.
  • the above-mentioned Hsp90 removing means means means capable of removing any mammalian Hsp90 protein, and includes, for example, means containing a Hsp90 removing substance (hereinafter also simply referred to as “Hsp90 removing substance”). can do.
  • Hsp90-removing substance include a substance that binds to Hsp90 (hereinafter also simply referred to as “Hsp90-binding substance”).
  • Hsp90-binding substance can be preferably exemplified. More preferred examples include antibodies, proteins, peptides, nucleic acids (preferably DNA), and low molecular weight compounds that bind to Hsp90.
  • antibodies, proteins, peptides, nucleic acids that specifically bind to Hsp90. More specifically, among them, antibodies and DNAs that specifically bind to Hsp90 can be more preferably exemplified because of their superior specificity and binding power to Hsp90. Specific binding to Hsp90 due to its excellent specificity and binding force for Hsp90. Antibodies can be particularly preferably exemplified that. Two or more kinds of Hsp90 removing substances may be used in combination.
  • Hsp90 binding substance is not particularly limited as long as it is a substance that binds to any mammalian Hsp90.
  • binding modes include hydrogen bonding, electrostatic bonding, van der Waals bonding, and hydrophobic bonding. (Hydrophobic interaction), covalent bond, ionic bond, and one or more bonds selected from coordination bonds can be exemplified, among them hydrogen bond, electrostatic bond, van der Waals bond, In addition, one or more bonds selected from hydrophobic bonds can be preferably exemplified.
  • An antibody that binds to Hsp90 is considered to be bound to Hsp90 due to the combined involvement of hydrogen bonds, electrostatic bonds, van der Waals bonds, and hydrophobic bonds.
  • the antibody that binds to Hsp90 include immunospecific antibodies such as monoclonal antibodies, polyclonal antibodies, chimeric antibodies, single chain antibodies, humanized antibodies, etc. It can illustrate more preferably in the point of the specificity.
  • the aforementioned antibody that binds to Hsp90 is produced by administering a fragment containing the Hsp90 or epitope or a cell expressing the protein on the membrane surface to an animal (preferably a non-human) using a conventional protocol,
  • the hybridoma method (Nature 256, 495-497, 1975), the trioma method, the human B cell hybridoma method (Immunology Today 4, 72, 1975) resulting in antibodies produced by continuous cell line cultures. 1983) and EBV-hybridoma method (MONOCLONAL ANTIBODIES AND CANCER THERAPY, pp. 77-96, Alan R. Liss, Inc., 1985) can be used.
  • Examples of the protein that binds to Hsp90 described above include Akt protein, HIF-1, ErbB1 / EGFR, ErbB2 / Her2, BCR-Abl, Raf1 and the like.
  • Examples of the nucleic acid (preferably DNA) that binds to the aforementioned Hsp90 include CpG-DNA, human DNA, bacteria / virus DNA, and the like.
  • a protein that binds to Hsp90 is isolated from a DNA sequence that encodes a target protein based on known sequence information, integrated into a suitable expression vector, and the resulting expression vector is introduced into a suitable cell. And it can manufacture by culturing such cells and isolating the target protein from such cells.
  • the nucleic acid that binds to Hsp90 is prepared by PCR using, for example, a primer for isolating the target nucleic acid based on known sequence information, and such a primer and a template DNA such as genomic DNA or cDNA. Can be manufactured.
  • Hsp90-binding substance whether or not a certain substance is an Hsp90-binding substance can be easily confirmed by, for example, contacting the labeled substance with solid-phased Hsp90, washing, and detecting the aforementioned label. be able to.
  • the suitable degree of the Hsp90 removal effect exhibited by the Hsp90 removal means in the present invention is not particularly limited, but the Hsp90 concentration in the serum when Hsp90 is removed from the serum of the SLE patient by the Hsp90 removal means is the SLE patient.
  • the ratio is preferably 10% or more, more preferably 20% or more, still more preferably 40% or more, more preferably 60% or more, and even more preferably 70% or more as a percentage of the serum Hsp90 concentration can do.
  • the “mammal” in the present specification is not particularly limited, but human, monkey, mouse, rat, hamster, guinea pig, cow, pig, horse, rabbit , Sheep, goats, cats, dogs and the like can be preferably exemplified, and humans can be more preferably exemplified.
  • the sequences of these mammalian Hsp90s can be easily obtained by accessing a database such as GenBank.
  • GenBank As an example of the sequence of Hsp90, the amino acid sequence of the coding region of human Hsp90 is shown in SEQ ID NO: 1.
  • “Mammalian Hsp90” in the present invention comprises an amino acid sequence having 80% or more, preferably 85% or more, more preferably 90% or more, and further preferably 95% or more identity with the amino acid sequence of SEQ ID NO: 1.
  • a protein having Hsp90 activity can be preferably exemplified.
  • the prophylactic / therapeutic effect on SLE exhibited by the prophylactic / therapeutic device of the present invention is not particularly limited as long as it is a prophylactic effect and / or therapeutic effect on SLE, but in particular, in blood, serum or in a mammalian subject
  • An increase inhibitory effect and a decrease effect of interferon ⁇ concentration in plasma can be preferably exemplified, and among these, the decrease effect can be more preferably exemplified.
  • the suitable degree of the interferon ⁇ concentration lowering effect exhibited by the preventive / therapeutic device of the present invention is not particularly limited, but in the following interferon ⁇ measurement assay, the preventive / therapeutic device of the present invention uses Hsp90
  • the interferon ⁇ concentration when the serum from which serum is removed is added is preferably 10% or more, more preferably 20% or more, still more preferably 30%, relative to the interferon ⁇ concentration when the serum of the same SLE patient is added. %, More preferably 40% or more, and still more preferably 50% or more.
  • the aspect of the Hsp90 removing substance in the preventive / therapeutic apparatus of the present invention is not particularly limited as long as it can remove Hsp90 in the blood, serum or plasma of the subject. Is preferably carried on a solid phase carrier.
  • the solid phase carrier is not particularly limited as long as it is a solid phase carrier to which the Hsp90 removal substance can be fixed, but examples of the material include gold, silver, copper, aluminum, platinum, titanium, nickel and the like.
  • Alloys such as stainless steel and duralumin; Glass materials such as silicon, glass, quartz glass, ceramics; Plastics such as polyester resin, polystyrene, polypropylene resin, nylon, epoxy resin, and vinyl chloride resin; Gels such as agarose; Dextran, Cellulose, polyvinyl alcohol, chitosan and the like can be exemplified, and examples of the shape include beads, granules, plates and membranes. In addition, when it is in the form of beads or granules, it can be used as a column for prevention / treatment of systemic lupus erythematosus by filling the column.
  • the Hsp90-removing substance When the Hsp90-removing substance is supported on a solid phase carrier, the Hsp90-removing substance can be produced by supporting it on the above-mentioned solid phase support.
  • the method for supporting the Hsp90-removing substance on the aforementioned solid phase carrier is not particularly limited, and conventionally known means such as a so-called physical bonding (adsorption) method, a chemical bonding method, or the like can be used.
  • the Hsp90 removing substance is immersed in an aqueous solution in which the Hsp90 removing substance is diluted to an appropriate concentration, then washed with a buffer solution, and dried. It can be supported on.
  • the surface of the solid support is coated with biotin, biotin is bound to the Hsp90 removal substance, and both of these biotins are bound via avidin,
  • the surface of the solid support is modified with an appropriate functional group (for example, a carboxyl group, an amino group, or a sulfhydryl group), and the functional group and the Hsp90 removing substance are cross-linked with a crosslinking agent (for example, carbodiimide or N-hydroxysuccinimide). Etc.), the Hsp90 removing substance can be supported on the solid phase carrier.
  • the preventive / therapeutic apparatus of the present invention is an apparatus further comprising “a means for bringing blood or the like into contact with the Hsp90 removing means” and / or “a means for separating blood or the like from the Hsp90 removing means” in addition to the Hsp90 removing means.
  • the apparatus further includes “a means for deriving blood or the like from the blood vessel of the subject” and / or “a means for introducing the blood or the like after separation into the blood vessel of the subject”. Can be exemplified. If these means are further provided, removal of Hsp90 can be performed more easily and quickly.
  • the prevention / treatment apparatus of the present invention may further contain a means for removing substances that can prevent or treat SLE when removed from blood or the like. .
  • the method for producing the preventive / therapeutic device of the present invention is not particularly limited as long as the device is provided with the Hsp90 removing means so that the Hsp90 removing effect can be exhibited.
  • the Hsp90 removing means is held on the support member.
  • the method of making it can be illustrated.
  • the preventive / therapeutic device of the present invention is provided with a part or all of the above-mentioned means in addition to the Hsp90 removing means, it can be produced by holding these means on a support member.
  • the blood of the subject is “means for deriving blood etc.
  • each means is held by the support member so as to pass through.
  • a means including a needle or a cannula is preferably exemplified.
  • a pump or the like for transferring the derived blood or the like to the “Hsp90 removing means” can be preferably exemplified.
  • a pump that sucks blood or the like and separates it from the Hsp90 removing means a centrifugal separator, or the like can be preferably exemplified.
  • the method for using the prophylactic / therapeutic device of the present invention is not particularly limited as long as the method includes the following steps A to C.
  • Step A contacting blood, serum or plasma (hereinafter collectively referred to as “blood etc.”) taken from the blood vessel of the subject with the Hsp90 removal means in the prevention / treatment apparatus of the present invention;
  • Step B a step of separating the Hsp90 removal means and blood, serum or plasma from the preventive / therapeutic device of the present invention;
  • Step C returning the separated blood, serum or plasma into the blood vessel of the subject;
  • the Hsp90 concentration in the blood, serum or plasma of the subject is reduced, thereby preventing SLE through suppression of interferon ⁇ production of the plasmacytoid dendritic cells of the subject. And / or it is considered that a therapeutic effect is exhibited.
  • a blood vessel of the subject's artery can be preferably exemplified.
  • the serum in the above step A can be obtained by separating blood and clots by leaving the blood taken out from the subject, etc., and removing the clots. After adding an anticoagulant to blood taken out from the specimen, it can be obtained as a supernatant from which cell components have been precipitated by centrifugation.
  • the method for taking out blood or the like from the blood vessel of the subject is not particularly limited, and a method using a syringe and a method of inserting a cannula into the blood vessel of the subject can be preferably exemplified.
  • the method of bringing blood or the like into contact with the Hsp90 removing means is not particularly limited, but a method of mixing blood or the like with the Hsp90 removing means can be preferably exemplified.
  • the method for separating the Hsp90 removing means from the blood or the like is not particularly limited, and a method of simply taking out the Hsp90 removing means from the blood or the like may be used, or the Hsp90 removing means and the blood or the like using centrifugation may be used. It is also possible to separate them.
  • a vein of the subject can be preferably exemplified.
  • the method of returning separated blood or the like into the blood vessel of the subject is not particularly limited, and a method using a syringe and a method of inserting a cannula into the blood vessel of the subject are preferably exemplified. Can do.
  • the frequency of use of the prophylactic / therapeutic device of the present invention is not particularly limited, but for example, use once a week (preferably twice or more, more preferably 3 times or more, more preferably 5 times or more), It can be suitably exemplified by continuing for 2 weeks or more (preferably 3 weeks or more, more preferably 6 weeks or more and 5 years or less, and further preferably 3 months or more and 5 years or less).
  • the onset of SLE can be more effectively suppressed or delayed at the stage before the onset of SLE, and the vicious circle of inflammation caused by SLE can be interrupted at the stage after the onset of SLE. Therefore, it is considered that a superior therapeutic effect for SLE is exhibited.
  • the preventive / therapeutic device of the present invention may be used together with a means for removing substance X other than Hsp90, which can obtain the effect of preventing / treating SLE by removing it from blood or the like. It may be used before or after use.
  • SLE can be particularly preferably exemplified as a disease to be prevented or treated by the prevention / treatment device of the present invention.
  • Autoimmune hepatitis (AIH) and primary bile are diseases similar to SLE.
  • AIH Autoimmune hepatitis
  • PBC cirrhosis of the liver
  • Mammals can be exemplified as the species of the subject to be prevented and treated by the prevention / treatment apparatus of the present invention.
  • the method for use as a biomarker for systemic lupus erythematosus of the present invention includes blood, serum or plasma.
  • Hsp90 preferably Hsp90 concentration
  • the method for determining systemic lupus erythematosus of the invention can be preferably exemplified.
  • the Hsp90 in the method of use of the present invention may be any mammalian Hsp90 as described above, and among them, the endogenous Hsp90 of any mammal can be preferably exemplified.
  • Method for determining systemic lupus erythematosus of the present invention includes (A) Hsp90 in blood, serum or plasma of a subject. Measuring the concentration in vitro; and (B) comparing and evaluating the Hsp90 concentration measured in the step (A) with the Hsp90 concentration in blood, serum or plasma of a normal control.
  • (D) the degree to which the Hsp90 concentration measured in the step (A) is higher than the Hsp90 concentration in normal control blood, serum or plasma can be suitably exemplified by a method comprising: evaluating the severity of a disease state of systemic lupus erythematosus of the subject.
  • the Hsp90 concentration in blood is measured in the step (A)
  • the Hsp90 concentration in blood of the normal control is used in the step (B)
  • the Hsp90 concentration in serum is measured in the step (A)
  • the plasma of the normal control is determined in the step (B).
  • Medium Hsp90 concentration is used.
  • the method for measuring the Hsp90 concentration in the step (A) in vitro is not particularly limited as long as it is a method capable of measuring the Hsp90 concentration in blood or the like in vitro.
  • Hsp90 ⁇ a method capable of measuring the Hsp90 concentration in blood or the like in vitro.
  • Hsp90 ⁇ a method capable of measuring the Hsp90 concentration in blood or the like in vitro.
  • ELISA kit manufactured by StressGen
  • a method for measuring using an anti-Hsp90 antibody can be exemplified.
  • the “Hsp90 concentration in blood, serum or plasma of a normal control” in the above step (B) may be measured when measuring the Hsp90 concentration in the blood of a subject or the like, or may be measured in advance. The numerical value may be used.
  • the method for comparison / evaluation in the step (B) is not particularly limited, but when the Hsp90 concentration measured in the step A is higher than the Hsp90 concentration in blood, serum or plasma of a normal control,
  • a method for evaluating the severity of the pathological condition of systemic lupus erythematosus of the subject ie, step (D) can be preferably exemplified.
  • a suitable level of the height of Hsp90 concentration measured in the step (A) when evaluating as systemic lupus erythematosus in the step (C) is not particularly limited, but the Hsp90 concentration measured in the step (A) is not particularly limited. However, it is preferably 2 times or more, more preferably 4 times or more, further preferably 6 times or more, more preferably 8 times or more, and still more preferably with respect to the Hsp90 concentration in normal control blood, serum or plasma. It can be suitably exemplified that it is 10 times or more, more preferably 12 times or more.
  • a symptom caused by an increase in interferon ⁇ concentration in blood or the like can be preferably exemplified.
  • the determination method of the present invention can determine (determine) whether or not the subject is SLE or the severity of the SLE disease state of the subject. In addition to this, the determination method of the present invention can also determine (determine) the possibility that the subject has SLE. In this case, instead of the above-mentioned step (C), (C ′) the level of the Hsp90 concentration measured in the step (A) is higher than the Hsp90 concentration in blood, serum or plasma of a normal control, A step of evaluating the degree of possibility that the subject has systemic lupus erythematosus is used.
  • the use of an Hsp90-removing substance in the production of the systemic lupus erythematosus prevention / treatment device of the present invention, the use of an Hsp90-removing substance, the method of using the Hsp90-removing substance as a systemic lupus erythematosus prevention / treatment device, In the prevention and treatment of systemic lupus erythematosus, the use of an Hsp90 removal substance, the step of bringing the Hsp90 removal substance into contact with blood taken out from the blood vessel of the subject, the step of separating the Hsp90 removal substance and blood, etc.
  • a method for preventing and treating systemic lupus erythematosus which includes step B of returning B and separated blood into the blood vessel of the subject, can also be exemplified.
  • step B of returning B and separated blood into the blood vessel of the subject can also be exemplified.
  • Hsp90 ⁇ The amount of Hsp90 in 5 types of serum samples, 4 types of serum samples collected from 2 SLE patients (SLE patient 1 and SLE patient 2) and 1 type of serum sample collected from healthy individuals, was expressed as Hsp90 ⁇ , ELISA. Measured with kit (manufactured by StressGen). The results of producing the Hsp90 concentration (pg / mL) in each serum sample from this measured value are shown in FIG.
  • Example 1 the results of the Hsp90 measurement assay as in Example 1 are shown in FIG.
  • the Hsp90 concentration in the serum was also high in the symptom exacerbation period, and a significant difference was observed between the healthy person and the post-treatment remission period (P ⁇ 0.01). From this, it was shown that the Hsp90 concentration in serum correlates with the activity of SLE. Therefore, the Hsp90 concentration in serum is considered to be very useful for the indication of the SLE disease state and the diagnosis of SLE.
  • concentration of Hsp90 is rising in the blood of a SLE patient. Since Hsp90 is not a secreted protein, it was unexpected that the concentration could be increased so much in the blood.
  • Interferon ⁇ measurement assay using human plasmacytoid dendritic cells A high level of interferon ⁇ in serum is considered to be one of the causes of SLE pathological deterioration.
  • the present inventors have previously shown that Hsp90 inhibitors can inhibit interferon ⁇ production from plasmacytoid dendritic cells derived from mice and humans, and systemic lupus erythematosus (SLE) model mice. It has been clarified that the disease state can be improved (Japanese Patent Application No. 2010-219422).
  • the following in vitro interferon ⁇ measurement assay is performed. Tried.
  • Peripheral blood was collected from the aforementioned healthy individuals, and human plasmacytoid dendritic cells were purified from the aforementioned peripheral blood using a human plasmacytoid dendritic cell isolation kit (Miltenyi Biotec). After seeding human plasmacytoid dendritic cells at 5 ⁇ 10 4 cells / well in a 96-well plate, 100 ⁇ L / well of the serum of the aforementioned SLE patient of Example 1 was added and cultured for 24 hours. Next, a culture supernatant was prepared from the culture solution, and the interferon ⁇ concentration in the culture supernatant was measured by ELISA.
  • concentration in a culture supernatant was measured by the same method except having added the serum which removed Hsp90 from the serum of this SLE patient.
  • the interferon ⁇ concentration in the culture supernatant was measured by the same method except that none of the aforementioned sera was added.
  • the removal of Hsp90 from the serum was performed using protein G beads to which the Fc site of the anti-Hsp90 antibody was bound. Specifically, such beads and serum were mixed well to bind the anti-Hsp90 antibody on the beads and Hsp90 in the serum, and then the beads were recovered to remove Hsp90 from the serum.
  • the results of measuring the interferon ⁇ concentration in the culture supernatant by the above-described methods are shown in FIG.
  • MRL / lpr mice which are SLE model mice, are prepared, before SLE develops (21 weeks old), when SLE begins to develop (28 weeks old), and after SLE develops
  • the concentration of Hsp90 in the serum at 37 weeks of age was measured in the same manner as in Example 1 using Hsp90 ⁇ , ELISA kit (manufactured by StressGen). The result is shown in FIG.
  • the present invention can be suitably used in the field of prevention / treatment of systemic lupus erythematosus, the field of biomarkers of systemic lupus erythematosus, and the field of determination of systemic lupus erythematosus.

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • External Artificial Organs (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne un dispositif pour la prophylaxie et le traitement du lupus érythémateux systémique, un procédé destiné à être utilisé comme biomarqueur du lupus érythémateux systémique, et un procédé permettant de déterminer le lupus érythémateux systémique. Selon l'invention, la prophylaxie/le traitement du lupus érythémateux systémique consiste à réduire la concentration de Hsp90 dans le sang, le sérum, ou le plasma sanguin d'un sujet en utilisant une substance pouvant enlever le Hsp90. Le procédé destiné à être utilisé comme biomarqueur du lupus érythémateux systémique consiste à utiliser le Hsp90 dans le sang, le sérum, ou le plasma sanguin d'un sujet comme biomarqueur. Le procédé permettant de déterminer le lupus érythémateux systémique selon l'invention consiste à comparer et évaluer la concentration de Hsp90 dans le sang, le sérum, ou le plasma sanguin d'un sujet par rapport à celle d'un témoin normal.
PCT/JP2011/078506 2010-12-10 2011-12-09 Dispositif pour la prophylaxie et le traitement du lupus érythémateux systémique WO2012077774A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2012547917A JP5916135B2 (ja) 2010-12-10 2011-12-09 全身性エリテマトーデスの予防・治療装置

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010-276407 2010-12-10
JP2010276407 2010-12-10

Publications (1)

Publication Number Publication Date
WO2012077774A1 true WO2012077774A1 (fr) 2012-06-14

Family

ID=46207256

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2011/078506 WO2012077774A1 (fr) 2010-12-10 2011-12-09 Dispositif pour la prophylaxie et le traitement du lupus érythémateux systémique

Country Status (2)

Country Link
JP (1) JP5916135B2 (fr)
WO (1) WO2012077774A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994007598A1 (fr) * 1992-09-25 1994-04-14 Otsuka Pharmaceutical Factory, Inc. Adsorbant pour fibronectine cellulaire, separation et purification de fibronectine et purification du sang
JP2002320671A (ja) * 2000-07-13 2002-11-05 Anawrahta Biotech Corp Ltd 体外免疫吸着装置
JP2004516896A (ja) * 2000-12-29 2004-06-10 アップフロント・クロマトグラフィー・アー／エス 細胞外体液からの特異的生体高分子物質の体外捕獲
JP2009529023A (ja) * 2006-03-06 2009-08-13 サントル・ナシオナル・ドゥ・ラ・ルシェルシュ・シアンティフィーク（セーエヌエールエス） アデニン由来化合物のループス治療への使用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5904663A (en) * 1997-07-30 1999-05-18 Braverman; Andrew Method of removing beta-2 microglobulin from blood
US20020197252A1 (en) * 2001-04-10 2002-12-26 Renal Tech International Selective adsorption devices and systems

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994007598A1 (fr) * 1992-09-25 1994-04-14 Otsuka Pharmaceutical Factory, Inc. Adsorbant pour fibronectine cellulaire, separation et purification de fibronectine et purification du sang
JP2002320671A (ja) * 2000-07-13 2002-11-05 Anawrahta Biotech Corp Ltd 体外免疫吸着装置
JP2004516896A (ja) * 2000-12-29 2004-06-10 アップフロント・クロマトグラフィー・アー／エス 細胞外体液からの特異的生体高分子物質の体外捕獲
JP2009529023A (ja) * 2006-03-06 2009-08-13 サントル・ナシオナル・ドゥ・ラ・ルシェルシュ・シアンティフィーク（セーエヌエールエス） アデニン由来化合物のループス治療への使用

Also Published As

Publication number Publication date
JPWO2012077774A1 (ja) 2014-05-22
JP5916135B2 (ja) 2016-05-11

Similar Documents

Publication Publication Date Title
Pietzsch et al. Human S100A12: a novel key player in inflammation?
Foell et al. Phagocyte-specific calcium-binding S100 proteins as clinical laboratory markers of inflammation
JP7260596B2 (ja) 細胞透過性タンパク質－抗体コンジュゲートおよび使用方法
Williams et al. Detection of nucleosome particles in serum and plasma from patients with systemic lupus erythematosus using monoclonal antibody 4H7.
CN106461681B (zh) 用于诊断血管疾病的生物标志物及其用途
JP7260248B2 (ja) 細胞透過性抗体
KR20170069262A (ko) Smad7 안티센스 올리고뉴클레오티드로 대상체를 치료하기 위한 방법 및 조성물
KR20140108718A (ko) 가와사키 질환용 바이오마커
JP2014518624A (ja) ニューログラニン診断キットのためのアッセイ試薬
JP7244423B2 (ja) 脳神経系疾患の治療または診断のための標的タンパク質としてのｐｃｎｔ
EP3176583B1 (fr) Diagnostic et traitement de maladie intestinale inflammatoire et du syndrome du côlon irritable
JP5916135B2 (ja) 全身性エリテマトーデスの予防・治療装置
WO2016117618A1 (fr) Procédé, kit, et biomarqueur de diagnostic de polyneuropathie démyélinisante inflammatoire chronique
JP2002355059A (ja) サイトカイン受容体ファミリー・クラス２の新規メンバー
CN110777201B (zh) 骨桥蛋白在缺氧缺血性脑损伤中的应用
KR102225039B1 (ko) Cd8+ 메모리 t 세포 매개성 질환의 예방 또는 치료용 약학 조성물
JPH06503647A (ja) ヒトホスホリパーゼ活性化タンパク質および慢性関節リウマチの診断の方法
TWI333978B (en) Granulysin and uses thereof
Chen et al. Ly6C-high monocytes alleviate brain injury in experimental subarachnoid hemorrhage in mice
KR20140123701A (ko) 신규한 간암치료 타겟으로서 sirt7의 용도
JP7409659B2 (ja) 新規サイトカイン、発現キット、およびその用途
WO2004092368A1 (fr) Etude de l'obesite ou de l'emaciation
WO2011088219A2 (fr) Agents thérapeutiques et méthodes de traitement des troubles immuns
JP3455782B2 (ja) 強皮症の診断薬
KR101970007B1 (ko) 자가면역 질환의 진단, 모니터링, 또는 예후 예측을 위해 생체 외 인터페론-감마의 양을 측정하는 방법

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11847753

Country of ref document: EP

Kind code of ref document: A1

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
ENP Entry into the national phase

Ref document number: 2012547917

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11847753

Country of ref document: EP

Kind code of ref document: A1